Alexander Hardy, CEO, Genentech: Is Business Going to Save the World?

TL;DR

Genentech CEO Alexander Hardy discusses the company's focus on addressing the COVID-19 pandemic while continuing to make progress in other disease areas. He emphasizes the importance of therapeutics and testing in managing the pandemic and highlights the need for public-private partnerships in drug development.

Transcript

[MUSIC] >> Today, we have the pleasure of talking to Alexander Hardy who is the current CEO of Genentech. A pharmaceutical company, a biotech firm and based in South San Francisco. Before coming on as CEO or starting to CEO, Alexander served as the head of Global Strategy for Roche Pharmaceuticals and he also at one time headed up Asia Pacific fero... Read More

Key Insights

• ❓ Genentech is focused on addressing the COVID-19 pandemic through the development of therapeutics and testing capabilities.
• 🪡 The company emphasizes the importance of public-private partnerships in drug development and the need for a balance between profit and societal impact.
• 🛄 Genentech recognizes the inequality in healthcare systems and aims to improve representation of minority populations in clinical studies.
• 👨‍🔬 The COVID-19 pandemic highlights the importance of innovation and the need for quick, transparent, and robust research to address global challenges.
• 🦺 The company is committed to ensuring the safety of its employees and maintaining the supply of essential drugs during the pandemic.
• 🥺 Genentech sees opportunities for new ways of working and collaboration that could lead to increased efficiency and progress in the life sciences industry.

Questions & Answers

Q: What is Genentech's main focus during the COVID-19 pandemic?

Genentech is focused on addressing the pandemic by developing therapeutics and testing capabilities for COVID-19. The company is working on a phase three study for a potential treatment for COVID-19 pneumonia and is also producing COVID-19 tests.

Q: What is the significance of phase three in drug development?

Phase three is the final stage of testing before a drug is approved. In this stage, the drug's efficacy and safety are studied on a larger scale, typically involving thousands of patients. Positive results from a phase three trial can lead to FDA approval for use in treating a specific condition.

Q: How does Genentech decide which diseases to focus on?

Genentech's focus is based on following the science and addressing significant unmet needs. The company gives its scientists autonomy to pursue their scientific hypotheses and applies a business lens later in the development process. The decision to prioritize certain diseases takes into account scientific understanding, patient unmet need, and business considerations.

Q: How does Genentech approach the balance between profit and societal impact?

Genentech believes in following the science and focusing on patients. While profitability is important, the company also recognizes the responsibility to make drugs accessible and address societal needs. Genentech aims to balance innovation with societal demands and maintain trust through transparency and responsible pricing.

Summary & Key Takeaways

• Genentech is focused on addressing the COVID-19 pandemic while continuing to make progress in other disease areas, such as oncology.

• The company is developing therapeutics and testing capabilities for COVID-19, with a focus on accessibility and global distribution.

• Alexander Hardy emphasizes the importance of public-private partnerships in drug development and the need to balance societal needs with profit considerations.